Aphria Inc. (APHA)
(Delayed Data from NYSE)
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
5 Top-Ranked Stocks to Tap Earnings Beat Potential
by Sanghamitra Saha
Forget earnings growth, bet on these top-ranked stocks to cash in on earnings beat.
Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Henry Schein (HSIC) sees dismal performance by Dental arm in Q1 due to disruptions resulting from the coronavirus pandemic.
Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.
What's in the Cards for Quidel (QDEL) This Earnings Season?
by Zacks Equity Research
Quidel (QDEL) is expected to have gained from its Molecular Diagnostic Solutions business in Q1.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q2
by Zacks Equity Research
Varian (VAR) continued to gain from core Oncology Systems segment in Q2.
Luminex (LMNX) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Luminex's (LMNX) first-quarter earnings benefit from solid performance across Consumable Sales, Assay, Service and Other Revenues.
CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.
Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Teleflex's (TFX) first-quarter 2020 results reflect sales growth across few major segments despite the coronavirus pandemic.
Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) benefits from increased product demand due to the coronavirus outbreak.
Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down
by Zacks Equity Research
The coronavirus impact results in inaccessibility of several of Syneos Health's (SYNH) clinical trial sites.
Genetic Testing Likely to Drive Invitae's (NVTA) Q1 Earnings
by Zacks Equity Research
Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q1.
PRA Health (PRAH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health's (PRAH) Clinical Research segment puts up a strong performance in Q1.
What's in the Cards for CVS Health (CVS) in Q1 Earnings?
by Zacks Equity Research
We expect CVS Health (CVS) to have gained from Aetna's addition of new Individual and Group Medicare Advantage members in Q1.
InMode (INMD) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
InMode's (INMD) Q1 performance is likely to have been driven by developments in business segments amid coronavirus-led supply disruptions.
What's in the Cards for DaVita (DVA)This Earnings Season?
by Zacks Equity Research
DaVita (DVA) is expected to have gained from Kidney Care segment in Q1.
What's in Store for Varian Medical (VAR) in Q2 Earnings?
by Zacks Equity Research
Varian's (VAR) solid Oncology platform is expected to have driven fiscal second-quarter performance.
Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View
by Zacks Equity Research
Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.
ResMed (RMD) Q3 Earnings Top on Higher Ventilator Sales
by Zacks Equity Research
ResMed's (RMD) adjusted gross margin improves on benefits from changes in product mix, and manufacturing and procurement efficiencies.
Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings gain from strong performance at MedSurg and Neurotechnology and Spine units.
IDEXX (IDXX) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
IDEXX Laboratories (IDXX) companion animal clinical visits decrease due to the impact of the coronavirus pandemic.
Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View
by Zacks Equity Research
Hologic (HOLX) exhibits robust segmental growth in second-quarter fiscal 2020, fueled by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.
QIAGEN (QGEN) Q1 Earnings to Gain on Growing Test Kit Sales
by Zacks Equity Research
QIAGEN (QGEN) is expected to have gained from increased adoption of testing solutions to identify the SARS-CoV-2 in Q1 amid the coronavirus pandemic.
ABIOMED (ABMD) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella saw decline in revenues within United States in Q4.
Align Technology (ALGN) Q1 Earnings Miss, Margins Down
by Zacks Equity Research
Align Technology's (ALGN) Scanner and Services reports COVID-19-led lower sales in North America and APAC region.